306 related articles for article (PubMed ID: 26762741)
1. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
Mazzone PJ; Wang XF; Beukemann M; Zhang Q; Seeley M; Mohney R; Holt T; Pappan KL
J Thorac Oncol; 2016 Jan; 11(1):72-8. PubMed ID: 26762741
[TBL] [Abstract][Full Text] [Related]
2. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
3. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
4. Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients.
Hocker JR; Deb SJ; Li M; Lerner MR; Lightfoot SA; Quillet AA; Hanas RJ; Reinersman M; Thompson JL; Vu NT; Kupiec TC; Brackett DJ; Peyton MD; Dubinett SM; Burkhart HM; Postier RG; Hanas JS
Cancer Invest; 2017 Oct; 35(9):573-585. PubMed ID: 28949774
[TBL] [Abstract][Full Text] [Related]
5. Exploratory investigation of plasma metabolomics in human lung adenocarcinoma.
Wen T; Gao L; Wen Z; Wu C; Tan CS; Toh WZ; Ong CN
Mol Biosyst; 2013 Sep; 9(9):2370-8. PubMed ID: 23857124
[TBL] [Abstract][Full Text] [Related]
6. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
[TBL] [Abstract][Full Text] [Related]
7. [The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer].
Kasprzyk M; Dyszkiewicz W; Zwaruń D; Leśniewska K; Wiktorowicz K
Pneumonol Alergol Pol; 2008; 76(5):321-6. PubMed ID: 19003761
[TBL] [Abstract][Full Text] [Related]
8. Identification of serum proteome components associated with progression of non-small cell lung cancer.
Pietrowska M; Jelonek K; Michalak M; Roś M; Rodziewicz P; Chmielewska K; Polański K; Polańska J; Gdowicz-Kłosok A; Giglok M; Suwiński R; Tarnawski R; Dziadziuszko R; Rzyman W; Widłak P
Acta Biochim Pol; 2014; 61(2):325-31. PubMed ID: 24872961
[TBL] [Abstract][Full Text] [Related]
9. Increased serum S-TRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age and smoking.
Kargi A; Bisgin A; Yalcin AD; Kargi AB; Sahin E; Gumuslu S
Asian Pac J Cancer Prev; 2013; 14(8):4819-22. PubMed ID: 24083751
[TBL] [Abstract][Full Text] [Related]
10. Limited Clinical Significance of Dimeric Form of Pyruvate Kinase as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Cancer.
Rzechonek A; Kaminska A; Mamczur P; Drapiewski A; Budzynski W
Adv Exp Med Biol; 2017; 955():51-57. PubMed ID: 27683215
[TBL] [Abstract][Full Text] [Related]
11. Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry.
Zeng X; Hood BL; Zhao T; Conrads TP; Sun M; Gopalakrishnan V; Grover H; Day RS; Weissfeld JL; Wilson DO; Siegfried JM; Bigbee WL
J Thorac Oncol; 2011 Apr; 6(4):725-34. PubMed ID: 21304412
[TBL] [Abstract][Full Text] [Related]
12. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
13. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer.
Song XY; Zhou SJ; Xiao N; Li YS; Zhen DZ; Su CY; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(8):4765-8. PubMed ID: 24083740
[TBL] [Abstract][Full Text] [Related]
14. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
15. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
[TBL] [Abstract][Full Text] [Related]
16. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
[TBL] [Abstract][Full Text] [Related]
17. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum amino acid profiles' utility in non-small cell lung cancer detection in Polish population.
Klupczynska A; Dereziński P; Dyszkiewicz W; Pawlak K; Kasprzyk M; Kokot ZJ
Lung Cancer; 2016 Oct; 100():71-76. PubMed ID: 27597283
[TBL] [Abstract][Full Text] [Related]
19. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G
Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401
[TBL] [Abstract][Full Text] [Related]
20. A metabolomic approach to lung cancer.
Hori S; Nishiumi S; Kobayashi K; Shinohara M; Hatakeyama Y; Kotani Y; Hatano N; Maniwa Y; Nishio W; Bamba T; Fukusaki E; Azuma T; Takenawa T; Nishimura Y; Yoshida M
Lung Cancer; 2011 Nov; 74(2):284-92. PubMed ID: 21411176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
